Checkpoint Therapeutics Receives Approval for PD-L1 Therapy December 16, 2024 The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
AIM at Melanoma Announces the Launch of AIM at Skin Cancer January 22, 2024 New Website Dedicated to Providing Individuals with Vital Knowledge and Tools to Protect Their Skin and Lead Healthy Lives January…
Jun. 03, 2025 Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence